Semaglutide research shows no increased cancer risk and rapid oral uptake

A large-scale study using national health records from Denmark, Sweden, and Norway has found no increased risk of pancreatic cancer among individuals taking semaglutide for type 2 diabetes. The research, presented at the European Association for the Study of Diabetes’s 2026 annual meeting, compared 97,464 semaglutide users against those taking other diabetes medications, such as sulfonylureas and insulin. The findings address safety concerns raised during the drug’s approval process, though researchers noted that the relatively short follow-up period may not capture long-term risks.

Separately, analysis of U.S. pharmacy prescription data indicates that oral semaglutide for obesity management has seen rapid adoption following its January 2026 FDA approval. The pill form surpassed 100,000 new prescriptions within two months of its launch. Researchers from the Johns Hopkins Ciccarone Center for Cardiovascular Disease Prevention found that the oral option attracted new patients to pharmacological obesity treatment rather than replacing injectable versions, potentially increasing the overall accessibility of weight-loss therapies.